Open access
Open access
Powered by Google Translator Translator

Vaccines

Phase 2 Trial | Maternal GBS6 vaccine shows promise in infant group B strep prevention

21 Jul, 2023 | 13:34h | UTC

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus – New England Journal of Medicine

Commentary: Maternal strep B vaccine slashes risk of infection among infants – CIDRAP

 


RCT | Single-Dose VLA1553 Chikungunya vaccine shows high immunogenicity and seems safe

23 Jun, 2023 | 13:38h | UTC

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial – The Lancet

News Release: First phase 3 trial of a chikungunya vaccine candidate finds it is generally safe and provokes an immune response – The Lancet

 

Commentary on Twitter

 


RCT | NmCV-5 pentavalent meningococcal vaccine shows non-inferiority to quadrivalent MenACWY-D in Mali and Gambia

30 May, 2023 | 11:46h | UTC

Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia – New England Journal of Medicine

 

Commentary on Twitter

 


RCT | Optimizing the timing of whooping cough immunization in mums through investigating pertussis vaccination in pregnancy

16 May, 2023 | 14:49h | UTC

Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial – Microbiome

 


RCT | Investigational 4-Antigen Staphylococcus aureus vaccine fails to prevent infections in spinal surgery

12 May, 2023 | 13:12h | UTC

Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STRIVE Randomized Clinical Trial – Clinical Infectious Diseases

 

Commentary on Twitter

 


FDA approves first Respiratory Syncytial Virus (RSV) vaccine

11 May, 2023 | 12:15h | UTC

FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine – U.S. Food & Drug Administration

Commentary: US FDA Approves First-Ever RSV Vaccine – Health Policy Watch

 


M-A | Association of SARS-CoV-2 vaccination or infection with Bell palsy

10 May, 2023 | 16:03h | UTC

Association of SARS-CoV-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-analysis – JAMA Otolaryngology–Head & Neck Surgery

 


RCT | Maternal RSVpreF vaccination protects infants from severe RSV illness

10 Apr, 2023 | 13:56h | UTC

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Vaccination during pregnancy could prevent RSV illness in infants – Charité – Universitätsmedizin Berlin

 

Commentary on Twitter

 


RCT | RSVpreF vaccine successfully prevents RSV-associated respiratory illness in seniors

10 Apr, 2023 | 13:54h | UTC

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults – New England Journal of Medicine (link to abstract – $ for full-text)

 


FDA panel endorses 2 RSV vaccines for older adults, but flag at potential increased risk of Guillain-Barre

8 Mar, 2023 | 14:27h | UTC

Pfizer vaccine:

In close vote, FDA advisers recommend Pfizer RSV vaccine for those 60 and older – CIDRAP

FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks – CNBC

GSK’s vaccine:

FDA panel recommends GSK’s RSV vaccine for ages 60 and up – CIDRAP

FDA advisors recommend GSK’s RSV vaccine for older adults, but flag potential safety risks – CNBC

See also: Rare neurological condition is ‘important potential risk’ of Pfizer’s RSV vaccine, FDA says – CNN

 


Phase 2b RCT | Ad26.RSV.preF–Respiratory Syncytial Virus preF protein vaccine is immunogenic in older adults

17 Feb, 2023 | 13:30h | UTC

Summary: A phase 2b clinical trial evaluated the Ad26.RSV.preF–RSV preF protein vaccine’s efficacy, immunogenicity, and safety in preventing RSV-mediated lower respiratory tract disease in adults aged 65 years and older. The vaccine was effective in preventing the disease and immunogenic, as demonstrated by the increase in RSV A2 neutralizing antibody titers after vaccination. The vaccine was associated with higher rates of adverse events than the placebo, but most were of mild to moderate severity. The trial concluded that Ad26.RSV.preF–RSV preF protein vaccine was effective in preventing RSV-mediated lower respiratory tract disease in older adults.*

Article: Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Ad26.RSV.preF-RSV preF Protein Vaccine Immunogenic in Seniors – HealthDay

 

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.

 


RCT | Respiratory Syncytial Virus prefusion F protein vaccine provides protection for older adults

17 Feb, 2023 | 13:32h | UTC

Summary: A phase 2b clinical trial evaluated the Ad26.RSV.preF–RSV preF protein vaccine in adults aged 65 years and older. The vaccine was effective and immunogenic, as demonstrated by the increase in RSV A2 neutralizing antibody titers after vaccination. The vaccine was associated with higher rates of adverse events than the placebo, but most were of mild to moderate severity.*

Article: Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.

 


RCT | Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age

17 Feb, 2023 | 13:27h | UTC

Summary: The study was a combined phase 2-3 clinical trial that aimed to determine whether the BNT162b2 vaccine was safe, could elicit an immune response and was effective in preventing COVID-19 in healthy children. The trial was conducted on children aged 6 months to 11 years, with the findings presented for the 6 months to 4 years age group. The results indicated that the vaccine was safe, immunogenic, and effective in reducing the risk of symptomatic COVID-19 by 73.2% in children aged 6 months to 4 years. The vaccine was well-tolerated, and the side effects were mainly mild to moderate. The incidence of fever was similar among those who received the vaccine or a placebo.*

Article: Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age – New England Journal of Medicine (link to abstract – $ for full-text)

 

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.

 


Recommended adult immunization schedule, United States, 2023

13 Feb, 2023 | 13:06h | UTC

Recommended Adult Immunization Schedule, United States, 2023 – Annals of Internal Medicine

Commentary: Recommended 2023 Adult Immunization Schedule Published – HealthDay

 

Commentary on Twitter

 


Updated child and adolescent immunization schedule, United States, 2023

13 Feb, 2023 | 13:05h | UTC

Child and Adolescent Immunization Schedule by Age – Centers for Diseases Control and Prevention

See also: Recommended Childhood and Adolescent Immunization Schedule: United States, 2023 – Pediatrics

Commentary: Immunization Schedule for Children, Teens Updated for 2023 – HealthDay

 


US infant pertussis incidence trends before and after implementation of the maternal Tdap vaccine

13 Feb, 2023 | 12:38h | UTC

US Infant Pertussis Incidence Trends Before and After Implementation of the Maternal Tetanus, Diphtheria, and Pertussis Vaccine – JAMA Pediatrics (free for a limited period)

Commentary: Maternal Tdap Vaccination Protects Youngest Infants From Pertussis – HealthDay

 

Commentary on Twitter

 


Guillain–Barré syndrome following influenza vaccination: a 15-year nationwide population-based case–control study

10 Feb, 2023 | 13:35h | UTC

Guillain–Barré syndrome following influenza vaccination: A 15-year nationwide population-based case–control study – European Journal of Neurology

Commentary: Influenza vaccination increases risk of Guillain-Barre syndrome within one month – Medical Dialogues

 


Case-control study | Effectiveness of a Meningococcal Group B vaccine (4CMenB) in children

9 Feb, 2023 | 13:59h | UTC

Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children – New England Journal of Medicine

Commentaries:

NEJM: Effectiveness of pediatric meningococcal B vaccine – MedicalResearch.com

4CMenB Vaccination Effective Against Invasive Meningococcal Disease in Children Under 5 – HealthDay

 

Commentary on Twitter

 


Cohort Study | Outcomes of Meningococcal B disease in children after implementation of routine 4CMenB vaccination

9 Feb, 2023 | 13:57h | UTC

Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study – The Lancet Child & Adolescent Health

 

Commentary on Twitter

 


Case-control study | Estimation of vaccine effectiveness of CoronaVac and BNT162b2 in patients with SARS-CoV-2 Omicron

6 Feb, 2023 | 13:32h | UTC

Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron – JAMA Network Open

 

Commentary on Twitter

 


The next generation of coronavirus vaccines: a graphical guide

3 Feb, 2023 | 14:18h | UTC

The next generation of coronavirus vaccines: a graphical guide – Nature

 


WHO updates recommendations on HPV vaccination schedule

9 Jan, 2023 | 14:57h | UTC

News Release: WHO updates recommendations on HPV vaccination schedule – World Health Organization

Guideline: Human papillomavirus vaccines: WHO position paper, December 2022 – World Health Organization

Commentaries: 

WHO Recommends One HPV Vaccine Dose Instead of Two; Move Should Help Expand Coverage – Health Policy Watch

WHO supports 1-dose HPV vaccine strategy – CIDRAP

 

Commentary on Twitter

 


RCTs | Vaccines for Zaire Ebola virus disease.

16 Dec, 2022 | 13:46h | UTC

Randomized Trial of Vaccines for Zaire Ebola Virus Disease – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Ebola vaccine regimens safe, immunogenic in adults and children – NIH News Releases

Commentaries: 

Ebola vaccine strategies show safety and immune response – CIDRAP

Trial on safety and immunogenicity of Ebola vaccines yields promising results – Institut National de la Sante et de la Recherche Medicale

 

Commentary on Twitter

 


Review | Human papillomavirus vaccination and cervical cancer risk.

16 Dec, 2022 | 13:26h | UTC

Human papillomavirus vaccination and cervical cancer risk – The BMJ

 


SR | Efficacy and safety of COVID‐19 vaccines.

8 Dec, 2022 | 13:04h | UTC

Efficacy and safety of COVID‐19 vaccines – Cochrane Library

Summary: What are the benefits and risks of vaccines for preventing COVID-19? – Cochrane Library

Commentary: Are COVID-19 vaccines effective and safe? New Cochrane evidence – Evidently Cochrane

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.